Anna C. Felmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna C. Felmer has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alexyss Guy
Department of Pharmacy, Cleveland Clinic Children’s Hospital, Cleveland, USA
1 shared publicationAmrita Nayak
Department of Pediatrics, Division of Neonatology, NYU Langone Hospital - Long Island, NYU Grossman Long Island School of Medicine, Mineola, USA
1 shared publicationAustin Han
Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Cohen Children’s Medical Center, Northwell Health, New Hyde Park, USA
1 shared publicationChristina Gerber
Department of Pharmacy, Rainbow Babies and Children’s Hospital, Cleveland, USA
1 shared publicationDave Gothard
Biostats Inc, East Canton, USA
1 shared publicationDiana Kwiatkowski
Department of Pharmacy, Mount Sinai Hospital, New York, USA
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-8
Comparison of growth and morbidity outcomes in preterm infants using two different intravenous lipid emulsions
Objectives: To compare growth z-scores and prematurity-related comorbidities for preterm infants receiving Soybean Oil-Intravenous Lipid Emulsion (SO-ILE) versus Soybean + Medium-chain triglycerides + Olive + Fish oil ILE (SMOF-ILE). Study design: A multicenter, retrospective cohort study of 347 preterm infants n = 179) demonstrated significantly improved growth for length ( p ≤ 0.001) and head circumference z-scores ( p = 0.015) at 36 weeks’ postmenstrual age and significantly worse growth for weight z-scores at 1 month ( p = 0.017) compared to the SMOF-ILE group ( n = 168). SO-ILE group had significantly lower rates of bronchopulmonary dysplasia (BPD) ( p < 0.001) and urinary tract infections (UTI) ( p = 0.045). Conclusion: In this population, SO-ILE had better outcomes for growth, BPD, and UTI compared to SMOF-ILE. Therefore, SO-ILE remains a reasonable lipid emulsion for preterm infants until more evidence is available.
- 8 October 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-8
Open AccessComparison of growth and morbidity outcomes in preterm infants using two different intravenous lipid emulsions
Objectives: To compare growth z-scores and prematurity-related comorbidities for preterm infants receiving Soybean Oil-Intravenous Lipid Emulsion (SO-ILE) versus Soybean + Medium-chain triglycerides + Olive + Fish oil ILE (SMOF-ILE). Study design: A multicenter, retrospective cohort study of 347 preterm infants n = 179) demonstrated significantly improved growth for length ( p ≤ 0.001) and head circumference z-scores ( p = 0.015) at 36 weeks’ postmenstrual age and significantly worse growth for weight z-scores at 1 month ( p = 0.017) compared to the SMOF-ILE group ( n = 168). SO-ILE group had significantly lower rates of bronchopulmonary dysplasia (BPD) ( p < 0.001) and urinary tract infections (UTI) ( p = 0.045). Conclusion: In this population, SO-ILE had better outcomes for growth, BPD, and UTI compared to SMOF-ILE. Therefore, SO-ILE remains a reasonable lipid emulsion for preterm infants until more evidence is available.